Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Industry, Sector and Symbol:
- Market Cap: $206.96 million
- Outstanding Shares: 46,093,000
- 50 Day Moving Avg: $3.53
- 200 Day Moving Avg: $3.26
- 52 Week Range: $2.25 - $4.85
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 23.63
- P/E Growth: 0.0000
- Annual Revenue: $20.41 million
- Price / Sales: 10.14
- Book Value: $0.56 per share
- Price / Book: 8.02
- EBIDTA: ($6,270,000.00)
- Net Margins: -52.09%
- Return on Equity: -63.19%
- Return on Assets: -41.08%
- Average Volume: 341,064 shs.
- Short Ratio: 11.53
Frequently Asked Questions for Chromadex Corp (OTCMKTS:CDXC)
What is Chromadex Corp's stock symbol?
Chromadex Corp trades on the OTCMKTS under the ticker symbol "CDXC."
How were Chromadex Corp's earnings last quarter?
Chromadex Corp (OTCMKTS:CDXC) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.09. The business had revenue of $5.31 million for the quarter, compared to analysts' expectations of $11 million. Chromadex Corp had a negative return on equity of 63.19% and a negative net margin of 52.09%. View Chromadex Corp's Earnings History.
When will Chromadex Corp make its next earnings announcement?
Where is Chromadex Corp's stock going? Where will Chromadex Corp's stock price be in 2017?
2 equities research analysts have issued 1-year price objectives for Chromadex Corp's shares. Their predictions range from $5.00 to $6.00. On average, they anticipate Chromadex Corp's stock price to reach $5.50 in the next year. View Analyst Ratings for Chromadex Corp.
What are analysts saying about Chromadex Corp stock?
Here are some recent quotes from research analysts about Chromadex Corp stock:
- 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (8/15/2017)
- 2. HC Wainwright analysts commented, "We note that the company’s revenues came in at $5.3M vs. our original forecast of $8M, while a net loss of $2.7M or $0.07 per share was also recorded vs. our projection for a positive EPS of $0.04. While R&D spending in the quarter was roughly in-line with our estimate at $728K vs. $700K, we note that COGS were slightly worse than our estimate, coming in at 57% vs. our projection of 49%. Given what we see as the current status of ChromaDex’s ingredients business, we have revised our 2017 revenue number to $24.3M, while we now project a net loss per share for 2017 of $0.14 vs. our prior forecast for EPS of $0.16 for the year." (8/11/2017)
Who are some of Chromadex Corp's key competitors?
Some companies that are related to Chromadex Corp include Corvus Pharmaceuticals (CRVS), Idera Pharmaceuticals (IDRA), NewLink Genetics Corporation (NLNK), Concert Pharmaceuticals (CNCE), Celldex Therapeutics (CLDX), Puretech Health PLC (PRTC), Novavax (NVAX), Arbutus Biopharma Corporation (ABUS), Protagonist Therapeutics (PTGX), Codexis (CDXS), Curis (CRIS), Nabriva Therapeutics AG (NBRV), Organovo Holdings (ONVO), Organovo Holdings (ONVO), Horizon Discovery Group PLC (HZD), Advaxis (ADXS), Merrimack Pharmaceuticals (MACK) and Compugen (CGEN).
Who are Chromadex Corp's key executives?
Chromadex Corp's management team includes the folowing people:
- Stephen Allen, Independent Chairman of the Board
- Frank L. Jaksch Jr., Chief Executive Officer, Director
- Thomas C. Varvaro, Chief Financial Officer, Secretary
- Troy Rhonemus, Chief Operating Officer
- Kurt A. Gustafson, Director
- Tony Lau, Director
- Steven D. Rubin Esq. J.D., Director
- Wendy Yu, Director
- Jeffrey Royston Baxter, Independent Director
Who owns Chromadex Corp stock?
Chromadex Corp's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.25%), Tieton Capital Management LLC (1.55%), North Star Investment Management Corp. (0.67%), Granite Investment Partners LLC (0.59%), Goldman Sachs Group Inc. (0.40%) and LMR Partners LLP (0.23%). Company insiders that own Chromadex Corp stock include Frank L Jaksch Jr, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Institutional Ownership Trends for Chromadex Corp.
Who sold Chromadex Corp stock? Who is selling Chromadex Corp stock?
Chromadex Corp's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc., Tieton Capital Management LLC, Granite Investment Partners LLC and Arete Wealth Advisors LLC. View Insider Buying and Selling for Chromadex Corp.
Who bought Chromadex Corp stock? Who is buying Chromadex Corp stock?
Chromadex Corp's stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., North Star Investment Management Corp., LMR Partners LLP and Bank of Montreal Can. Company insiders that have bought Chromadex Corp stock in the last two years include Frank L Jaksch Jr, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Insider Buying and Selling for Chromadex Corp.
How do I buy Chromadex Corp stock?
Shares of Chromadex Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chromadex Corp's stock price today?
MarketBeat Community Rating for Chromadex Corp (OTCMKTS CDXC)MarketBeat's community ratings are surveys of what our community members think about Chromadex Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Chromadex Corp stock can currently be purchased for approximately $4.49.
Consensus Ratings for Chromadex Corp (OTCMKTS:CDXC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$5.50|
Analysts' Ratings History for Chromadex Corp (OTCMKTS:CDXC)
(Data available from 9/21/2015 forward)
|9/11/2017||HC Wainwright||Reiterated Rating||Buy|
|1/3/2017||Rodman & Renshaw||Initiated Coverage||Buy||$6.00|
Earnings History for Chromadex Corp (OTCMKTS:CDXC)Earnings History by Quarter for Chromadex Corp (OTCMKTS CDXC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/10/2017||Q2 2017||$0.04||($0.05)||$11.00 million||$5.31 million||View||N/A|
|3/16/2017||Q4 2016||($0.01)||($0.06)||$5.60 million||$5.64 million||View||N/A|
|11/10/2016||Q3 2016||($0.03)||$5.01 million||View||Listen|
|8/11/2016||Q216||$0.01||$6.10 million||$8.80 million||View||Listen|
|5/12/2016||Q116||$0.01||$5.30 million||$7.30 million||View||Listen|
Earnings Estimates for Chromadex Corp (OTCMKTS:CDXC)
Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $0.19 EPS
Dividend History for Chromadex Corp (OTCMKTS:CDXC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Chromadex Corp (OTCMKTS:CDXC)Insider Trades by Quarter for Chromadex Corp (OTCMKTS:CDXC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/25/2017||Stephen R Allen||Director||Buy||2,000||$3.31||$6,620.00|| |
|8/18/2017||Step Holdings Ltd Pioneer||Major Shareholder||Buy||786,167||$2.60||$2,044,034.20|| |
|8/15/2017||Robert N Fried||Insider||Buy||10,000||$3.15||$31,500.00|| |
|5/24/2017||Step Holdings Ltd Pioneer||Major Shareholder||Buy||2,521,526||$2.60||$6,555,967.60|| |
|5/19/2017||Stephen R Allen||Director||Buy||3,000||$3.20||$9,600.00|| |
|3/20/2017||Stephen R Allen||Director||Buy||2,000||$2.81||$5,620.00|| |
|12/12/2016||Frank L Jaksch Jr||CEO||Buy||2,000||$2.42||$4,840.00|| |
|9/1/2016||Frank L Jaksch Jr||CEO||Buy||1,500||$3.32||$4,980.00|| |
|9/1/2016||Robert N Fried||Director||Buy||15,000||$3.39||$50,850.00|| |
|6/20/2016||Troy Allen Rhonemus||COO||Buy||7,800||$3.47||$27,066.00|| |
Headline Trends for Chromadex Corp (OTCMKTS:CDXC)
Latest Headlines for Chromadex Corp (OTCMKTS:CDXC)
|ChromaDex to Present at the Ladenburg Thalmann 2017 Healthcare Conference - Nasdaq|
www.nasdaq.com - September 21 at 10:49 AM
|ChromaDex to Showcase Healthy Aging Ingredients and Phytochemical Reference Standards at SupplySide West 2017|
finance.yahoo.com - September 18 at 3:35 PM
|Chromadex Corp (CDXC) & Codexis (CDXS) Critical Analysis|
www.americanbankingnews.com - September 17 at 12:32 AM
|ETFs with exposure to Chromadex Corp. : September 14, 2017|
finance.yahoo.com - September 14 at 10:48 PM
|Chromadex Corp. :CDXC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017|
finance.yahoo.com - September 13 at 6:18 PM
|Chromadex Corp (CDXC) Given Buy Rating at HC Wainwright|
www.americanbankingnews.com - September 11 at 8:58 PM
|ValuEngine Upgrades Chromadex Corp (CDXC) to "Hold"|
www.americanbankingnews.com - September 9 at 11:18 AM
|Baystreet.ca - ChromaDex Teams Up with AS Watson to Bring TRU ... - Baystreet.ca|
www.baystreet.ca - September 8 at 3:14 AM
|ChromaDex Partners with Asia's Leading Health and Beauty ... - Nasdaq|
www.nasdaq.com - September 8 at 3:14 AM
|ChromaDex Teams Up with AS Watson to Bring TRU NIAGEN to Asia and Europe|
www.baystreet.ca - September 7 at 5:09 PM
|ChromaDex Partners with Asia’s Leading Health and Beauty Retailer, Watsons, for TRU NIAGEN™ Retail Launch|
finance.yahoo.com - September 7 at 5:09 PM
|LabCorp Completes $1.2-Billion Chiltern Buyout, Boosts CRO|
www.nasdaq.com - September 4 at 5:04 PM
|LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval|
www.zacks.com - August 28 at 4:58 PM
|LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track|
www.nasdaq.com - August 24 at 5:09 PM
|ChromaDex (CDXC) Sells Analytical Testing Business to LabCorp (LH) - StreetInsider.com|
www.streetinsider.com - August 23 at 10:22 PM
|ChromaDex (CDXC) Sells Analytical Testing Business to LabCorp (LH)|
www.streetinsider.com - August 23 at 5:21 PM
|ChromaDex Sells its Analytical Testing Business to LabCorp, to Accelerate the Expansion of Nicotinamide Riboside and its Other Patented Ingredient Technologies|
finance.yahoo.com - August 23 at 5:20 PM
|LabCorp purchases analytical testing services business in $8.5 million deal|
finance.yahoo.com - August 23 at 5:20 PM
|Step Holdings Ltd Pioneer Buys 786,167 Shares of Chromadex Corp (CDXC) Stock|
www.americanbankingnews.com - August 22 at 10:36 AM
|Company Appoints Tony Lau and Wendy Yu to Board of Directors|
globenewswire.com - August 21 at 4:54 PM
|ChromaDex Announces Closing of Third and Final Tranche of the $25 Million Strategic Investment Led|
www.nasdaq.com - August 21 at 4:54 PM
|Robert N. Fried Acquires 10,000 Shares of Chromadex Corp (CDXC) Stock|
www.americanbankingnews.com - August 16 at 9:36 PM
|Zacks Investment Research Lowers Chromadex Corp (CDXC) to Strong Sell|
www.americanbankingnews.com - August 15 at 6:08 PM
|HC Wainwright Reiterates $5.00 Price Target for Chromadex Corp (OTCMKTS:CDXC)|
www.americanbankingnews.com - August 13 at 4:38 PM
|Edited Transcript of CDXC earnings conference call or presentation 10-Aug-17 8:30pm GMT|
finance.yahoo.com - August 11 at 5:30 PM
|ChromaDex's (CDXC) CEO Frank Jaksch on Q2 2017 Results - Earnings Call Transcript|
seekingalpha.com - August 10 at 11:20 PM
|Chromadex Corp (OTCMKTS:CDXC) Posts Earnings Results, Misses Estimates By $0.11 EPS|
www.americanbankingnews.com - August 10 at 8:46 PM
|ChromaDex Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 10 at 6:17 PM
|ChromaDex reports 2Q loss|
finance.yahoo.com - August 10 at 6:17 PM
|Chromadex Corp (OTCMKTS:CDXC) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - August 4 at 3:08 PM
|ChromaDex® to Report Second Quarter 2017 Financial Results on ... - Nasdaq|
www.nasdaq.com - August 4 at 4:39 AM
|ChromaDex® to Report Second Quarter 2017 Financial Results on Thursday, August 10, 2017|
finance.yahoo.com - August 3 at 6:36 PM
|ETFs with exposure to Chromadex Corp. : August 1, 2017|
finance.yahoo.com - August 1 at 8:36 PM
|ChromaDex: New Cash, New Strategy: Will Success Follow? - Seeking Alpha|
seekingalpha.com - July 25 at 4:59 PM
|Chromadex Corp (OTCMKTS:CDXC) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - July 17 at 5:20 PM
|ETFs with exposure to Chromadex Corp. : July 13, 2017|
finance.yahoo.com - July 13 at 6:07 PM
|ChromaDex Sponsors Global Gathering of Scientific Leaders in NAD+ Metabolism and Signaling at the 2|
www.nasdaq.com - July 10 at 10:03 PM
|ChromaDex Sponsors Global Gathering of Scientific Leaders in NAD+ Metabolism and Signaling at the 2017 Federation of American Societies for Experimental Biology Conference|
finance.yahoo.com - July 10 at 5:01 PM
|Chromadex Corp (CDXC) Downgraded by ValuEngine|
www.americanbankingnews.com - July 1 at 10:04 AM
|ChromaDex (CDXC) Appoints Dr. Rudolph Tanzi, Harvard Neurology Professor to Scientific Advisory Board|
www.streetinsider.com - June 27 at 4:27 PM
|ChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific Advisory Board|
finance.yahoo.com - June 27 at 4:27 PM
|ETFs with exposure to Chromadex Corp. : June 26, 2017|
finance.yahoo.com - June 26 at 4:54 PM
|ETFs with exposure to Chromadex Corp. : June 16, 2017|
finance.yahoo.com - June 16 at 4:58 PM
|Chromadex Corp. :CDXC-US: Earnings Analysis: Q1, 2017 By the Numbers : June 15, 2017|
finance.yahoo.com - June 15 at 5:59 PM
|Chromadex Joins with Scripps on Breast Cancer Treatment|
www.baystreet.ca - June 13 at 12:45 PM
|ChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN® in treating breast cancer|
finance.yahoo.com - June 12 at 5:15 PM
|ChromaDex Names World’s Leading Expert on Nicotinamide Riboside and NAD as Chief Scientific Advisor|
finance.yahoo.com - June 5 at 12:20 PM
|NIAGEN® nicotinamide riboside launches into the functional food space|
finance.yahoo.com - May 31 at 10:17 AM
|Chromadex Corp (CDXC) Major Shareholder Step Holdings Ltd Pioneer Acquires 2,521,526 Shares|
www.americanbankingnews.com - May 26 at 10:35 AM
|ChromaDex Announces Closing of Second Tranche of the $25 Million Strategic Investment Led by Mr. Li Ka-shing|
finance.yahoo.com - May 25 at 5:40 PM
Chromadex Corp (CDXC) Chart for Thursday, September, 21, 2017